Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension

✍ Scribed by Barnett, A. H.; Patel, S.; Harper, R.; Toorawa, R.; Thiemann, S.; von Eynatten, M.; Woerle, H.-J.

• Book ID: 119827941
• Publisher: John Wiley and Sons
• Year: 2012
• Tongue: English
• Weight: 619 KB
• Volume: 14
• Category: Article
• ISSN: 1462-8902
• DOI: 10.1111/dom.12011